Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 735 across all filing types
Latest filing 2021-10-21 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
首次公开发行股票并在创业板上市发行结果公告
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行结果公告" which translates to "Issuance Results Announcement" for the company's initial public offering (IPO) and listing on the Growth Enterprise Market (创业板). It details the final subscription and allotment results of the IPO shares, including strategic placement, online and offline subscription numbers, pricing, and underwriting details. The document is relatively short (3384 characters) and focuses on the announcement of the issuance results rather than the full financial report or prospectus. This matches the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes related to the IPO. It is not an Annual Report, Earnings Release, nor a Regulatory Filing. Therefore, the correct classification is CAP with high confidence.
2021-10-21 Chinese
首次公开发行股票并在创业板上市网下初步配售结果公告
Capital/Financing Update Classification · 100% confidence The document is titled as "新乡拓新药业股份有限公司首次公开发行股票并在创业板上市网下初步配售结果公告" which translates to "Announcement of the Preliminary Offline Allotment Results for the Initial Public Offering and Listing on the ChiNext Board of Xinxiang Tuoxin Pharmaceutical Co., Ltd.". It details the initial public offering (IPO) share allotment, pricing, strategic placement, subscription results, and payment instructions. It includes detailed tables of allotment results and investor subscription data. The document is an announcement of the allotment results related to a capital raising event (IPO). It is not a full financial report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. It is not a regulatory certification or legal proceeding. The content focuses on the capital issuance and allotment process. Therefore, the document fits best under the category "Capital/Financing Update (CAP)" which covers updates on company fundraising and financing activities such as IPO allotment results.
2021-10-19 Chinese
首次公开发行股票并在创业板上市网上摇号中签结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement of the lottery results for the online subscription of shares in the initial public offering (IPO) of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the subscription process, payment obligations, and the winning numbers for the share allocation. The document does not contain financial statements or detailed financial data but is focused on the allocation and subscription results of the IPO shares. This fits the category of Capital/Financing Update (CAP), as it relates to the company's fundraising activity through the IPO and the allocation of shares.
2021-10-19 Chinese
首次公开发行股票并在创业板上市网上申购情况及中签率公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of Xinxiang Tuoxin Pharmaceutical Co., Ltd., detailing the subscription situation, allocation rates, pricing, and the lottery process for the online subscription. It includes information about the underwriting, strategic placement, and the allotment results. The document does not contain financial statements or detailed financial performance data but rather provides procedural and subscription outcome information related to the IPO. It is not a full financial report, earnings release, or management discussion. The document is also relatively short (3550 characters) and serves as an official announcement of subscription results and allocation rates for the IPO. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-10-18 Chinese
广东华商律师事务所关于公司首次公开发行股票并在创业板上市战略投资者专项核查法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the strategic investor verification for a company's initial public offering (IPO) and listing on the ChiNext board. It discusses the qualifications, selection criteria, and compliance of strategic investors involved in the IPO. The content focuses on legal compliance and verification related to the IPO process, specifically the strategic placement of shares to certain investors. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of a report but a legal opinion related to the IPO process. This type of document fits best under Regulatory Filings (RNS) as it is a compliance/legal document related to securities issuance and does not fit other more specific categories like Annual Report, Earnings Release, or Capital/Financing Update.
2021-10-14 Chinese
首次公开发行股票并在创业板上市投资风险特别公告
Capital/Financing Update Classification · 95% confidence The document is titled as a "首次公开发行股票并在创业板上市投资风险特别公告" which translates to "Initial Public Offering (IPO) and Listing on the Growth Enterprise Market - Special Investment Risk Announcement." It details the IPO process, pricing, allocation, regulatory approvals, and investment risks associated with the IPO of 新乡拓新药业股份有限公司. The document includes detailed information about the offering size, pricing, underwriting, subscription process, lock-up periods, and risk factors for investors. It is not a financial report like an Annual Report or Interim Report, nor is it a simple announcement of a report publication. It is a detailed announcement related to capital raising and financing activities, specifically the IPO and listing process. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (8400 characters) and content confirm it is a substantive announcement, not a brief notice or certification.
2021-10-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.